MX2024000690A - Composiciones farmaceuticas de un anticuerpo b7-h3 y uso de las mismas. - Google Patents
Composiciones farmaceuticas de un anticuerpo b7-h3 y uso de las mismas.Info
- Publication number
- MX2024000690A MX2024000690A MX2024000690A MX2024000690A MX2024000690A MX 2024000690 A MX2024000690 A MX 2024000690A MX 2024000690 A MX2024000690 A MX 2024000690A MX 2024000690 A MX2024000690 A MX 2024000690A MX 2024000690 A MX2024000690 A MX 2024000690A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- antibody
- same
- provides
- enoblituzumab
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163222750P | 2021-07-16 | 2021-07-16 | |
| PCT/US2022/073462 WO2023288173A1 (en) | 2021-07-16 | 2022-07-06 | Pharmaceutical compositions of a b7-h3 antibody and use of the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024000690A true MX2024000690A (es) | 2024-02-07 |
Family
ID=84920541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024000690A MX2024000690A (es) | 2021-07-16 | 2022-07-06 | Composiciones farmaceuticas de un anticuerpo b7-h3 y uso de las mismas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240336687A1 (https=) |
| EP (1) | EP4370155A4 (https=) |
| JP (1) | JP2024526773A (https=) |
| KR (1) | KR20240038005A (https=) |
| CN (1) | CN117715657A (https=) |
| AU (1) | AU2022310668A1 (https=) |
| CA (1) | CA3224118A1 (https=) |
| IL (1) | IL310187A (https=) |
| MX (1) | MX2024000690A (https=) |
| TW (1) | TW202310874A (https=) |
| WO (1) | WO2023288173A1 (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12012501751A1 (en) * | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| WO2019246312A1 (en) * | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| BR112022019073A2 (pt) * | 2020-03-25 | 2022-11-08 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Composição farmacêutica que compreende conjugado anticorpo-fármaco e uso da mesma |
-
2022
- 2022-07-06 EP EP22842996.5A patent/EP4370155A4/en not_active Withdrawn
- 2022-07-06 IL IL310187A patent/IL310187A/en unknown
- 2022-07-06 CN CN202280050225.0A patent/CN117715657A/zh active Pending
- 2022-07-06 US US18/577,945 patent/US20240336687A1/en active Pending
- 2022-07-06 KR KR1020247004914A patent/KR20240038005A/ko active Pending
- 2022-07-06 AU AU2022310668A patent/AU2022310668A1/en active Pending
- 2022-07-06 MX MX2024000690A patent/MX2024000690A/es unknown
- 2022-07-06 JP JP2024502056A patent/JP2024526773A/ja active Pending
- 2022-07-06 WO PCT/US2022/073462 patent/WO2023288173A1/en not_active Ceased
- 2022-07-06 CA CA3224118A patent/CA3224118A1/en active Pending
- 2022-07-12 TW TW111126185A patent/TW202310874A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3224118A1 (en) | 2023-01-19 |
| AU2022310668A1 (en) | 2024-01-18 |
| IL310187A (en) | 2024-03-01 |
| WO2023288173A1 (en) | 2023-01-19 |
| EP4370155A4 (en) | 2025-06-11 |
| JP2024526773A (ja) | 2024-07-19 |
| CN117715657A (zh) | 2024-03-15 |
| KR20240038005A (ko) | 2024-03-22 |
| US20240336687A1 (en) | 2024-10-10 |
| EP4370155A1 (en) | 2024-05-22 |
| TW202310874A (zh) | 2023-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4685160A3 (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| CR20220614A (es) | 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer | |
| Bosco et al. | Principles of antibiotic prophylaxis in total joint arthroplasty: current concepts | |
| Shekarian et al. | Paradigm shift in oncology: targeting the immune system rather than cancer cells | |
| SA521430342B1 (ar) | تركيبة سائلة تشتمل على جسم مضاد لمستقبل ألفا إنترليوكين -4 البشري | |
| WO2019136300A3 (en) | Anti-mct1 antibodies and uses thereof | |
| Khan et al. | Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer | |
| McMillan et al. | Antibody-drug conjugates for multiple myeloma | |
| Rasche et al. | Novel immunotherapies in multiple myeloma–chances and challenges | |
| PH12020500205A1 (en) | Anti-cd147 antibody | |
| WO2021207433A3 (en) | Epitopes of sars-cov-2 neutralizing antibodies | |
| Parrondo et al. | Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives | |
| Van de Donk et al. | S183: novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: updated phase 1B results for talquetamab (a GPRC5D X CD3 bispecific antibody) in combination with daratumumab | |
| WO2022047047A8 (en) | Inhalable therapeutic agents | |
| MX2025005092A (es) | Anticuerpo anti-trem2 y usos del mismo | |
| WO2025117894A3 (en) | Dimeric immunoconjugates for use in treating cancers and methods of use | |
| MX2024000690A (es) | Composiciones farmaceuticas de un anticuerpo b7-h3 y uso de las mismas. | |
| MX2023004533A (es) | Formulaciones de anticuerpos anti-siglec-8. | |
| Hosen | Chimeric antigen receptor T-cell therapy for multiple myeloma | |
| WO2022022464A8 (zh) | 新型双特异性抗cd3/cd20多肽复合物配制剂 | |
| Verkleij et al. | Immunotherapy in multiple myeloma: when, where, and for who? | |
| WO2022023566A3 (en) | Cd-3 antibodies for the treatment of coronavirus | |
| MX2024000268A (es) | Composiciones farmaceuticas de un anticuerpo contra pd-1 y uso de las mismas. | |
| Polito et al. | ATG‐saporin‐S6 immunotoxin: a new potent and selective drug to eliminate activated lymphocytes and lymphoma cells | |
| MX2025002839A (es) | Combinacion farmaceutica y uso de la misma |